ORCL Research Update — September 11, 2026 (Updated)

Updated Thesis

Oracle is a global enterprise software and cloud infrastructure provider whose portfolio spans the Oracle Database, Java, Fusion Cloud SaaS applications (ERP, EPM, SCM, HCM), NetSuite, and Oracle Cloud Infrastructure, sold through a direct sales force to businesses, governments, and educational institutions worldwide. The business quality is high on fundamentals: trailing-twelve-month gross margin is 63.9%, operating margin 32.4%, net margin 26.4%, and ROE is 42.6%, while revenue grew 29.6% and earnings grew 62.6% in the most recent quarter, reflecting the scale of its installed base and the ramp of OCI. The shares are mispriced to the downside of blended fair value: at $149.12 the stock trades at 5.98 times sales, 23.38 times trailing earnings, and 14.56 times EV/EBITDA, versus a fair value estimate of $216.22 (about 45% upside) and an analyst consensus Strong Buy with a $238.67 average target (about 60% upside).

The investment grade as of this refresh is B — solid business quality. A-tier business, B-tier valuation with 45% upside to blended fair value.

Key Metrics at a Glance

Current price: $149.12

These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.

Our 12–18 Month Outlook

Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Oracle Corporation remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.

Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.

[View full ORCL research →](/stocks/ORCL)